Alnylam Ready To Expand TTR Franchise With Positive Cardiomyopathy Results
Supplemental Onpattro US Filing Planned For Late 2022
Executive Summary
ATTR amyloidosis patients with cardiomyopathy had statistically significant functional and quality of life improvements when treated with Onpattro (patisiran) in the Phase III APOLLO-B study.
You may also be interested in...
BridgeBio Comes Back With Positive Phase III Results For Acoramidis In ATTR-CM
The ATTRibute-CM study met its primary endpoint as well as key secondary endpoints, and the company plans to file for US FDA approval before the end of 2023.
Medicare Price ‘Negotiation’ Process Gets Broad Brush Treatment In New Law
With enactment of the drug pricing reform provisions in the Inflation Reduction Act, stakeholders now turn their attention to the implementing regulations that will be developed by the Centers for Medicare and Medicaid Services.
Medicare Price ‘Negotiation’ Process Gets Broad Brush Treatment In New Law
With enactment of the drug pricing reform provisions in the Inflation Reduction Act, stakeholders now turn their attention to the implementing regulations that will be developed by the Centers for Medicare and Medicaid Services.